BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 15570000)

  • 1. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin.
    Goto H; Yano S; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Clin Cancer Res; 2004 Nov; 10(22):7671-6. PubMed ID: 15570000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of a new vascular targeting agent, ZD6126, in pulmonary metastases by human lung adenocarcinoma in nude mice.
    Goto H; Yano S; Zhang H; Matsumori Y; Ogawa H; Blakey DC; Sone S
    Cancer Res; 2002 Jul; 62(13):3711-5. PubMed ID: 12097279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
    Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
    Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
    Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor interaction of short-course endostatin and ionizing radiation.
    Hanna NN; Seetharam S; Mauceri HJ; Beckett MA; Jaskowiak NT; Salloum RM; Hari D; Dhanabal M; Ramchandran R; Kalluri R; Sukhatme VP; Kufe DW; Weichselbaum RR
    Cancer J; 2000; 6(5):287-93. PubMed ID: 11079167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.
    Davis PD; Dougherty GJ; Blakey DC; Galbraith SM; Tozer GM; Holder AL; Naylor MA; Nolan J; Stratford MR; Chaplin DJ; Hill SA
    Cancer Res; 2002 Dec; 62(24):7247-53. PubMed ID: 12499266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of the antivascular agent ZD6126 with hypoxic cytotoxin treatment, with reference to the effect on quiescent tumor cells and the dependency on p53 status of tumor cells.
    Masunaga S; Nagasawa H; Uto Y; Hori H; Ohnishi K; Takahashi A; Ohnishi T; Suzuki M; Nagata K; Kinashi Y; Ono K
    Oncol Rep; 2005 Aug; 14(2):393-400. PubMed ID: 16012721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
    Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
    Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
    Medinger M; Esser N; Soltau J; Lehmann KM; Konerding MA; Wolloscheck T; Ryan AJ; Drevs J
    Int J Oncol; 2011 Feb; 38(2):455-64. PubMed ID: 21152862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
    Zhang P; He JB; Ou LW; Wang XH
    Ai Zheng; 2006 Apr; 25(4):409-13. PubMed ID: 16613671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy.
    Masunaga S; Sakurai Y; Suzuki M; Nagata K; Maruhashi A; Kinash Y; Ono K
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):920-7. PubMed ID: 15465210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
    Evelhoch JL; LoRusso PM; He Z; DelProposto Z; Polin L; Corbett TH; Langmuir P; Wheeler C; Stone A; Leadbetter J; Ryan AJ; Blakey DC; Waterton JC
    Clin Cancer Res; 2004 Jun; 10(11):3650-7. PubMed ID: 15173071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
    Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
    Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
    Beerepoot LV; Radema SA; Witteveen EO; Thomas T; Wheeler C; Kempin S; Voest EE
    J Clin Oncol; 2006 Apr; 24(10):1491-8. PubMed ID: 16574998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent.
    Micheletti G; Poli M; Borsotti P; Martinelli M; Imberti B; Taraboletti G; Giavazzi R
    Cancer Res; 2003 Apr; 63(7):1534-7. PubMed ID: 12670901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor immunoneutralization in combination with cisplatin reduces EAC tumor growth.
    Ghosh S; Maity P
    Int Immunopharmacol; 2006 Oct; 6(10):1550-9. PubMed ID: 16919827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.